Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thierry Poynard

Showing results (181-190 of 222) with videos related to

Pageof 23
Sort By:
Plos One|July 4, 2008
An accurate definition of the status of inactive hepatitis B virus carrier by a combination of biomarkers (FibroTest-ActiTest) and viral loadYen Ngo, Yves Benhamou, Vincent Thibault, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|January 31, 2007
Effect of prolonged interferon therapy on the outcome of hepatitis C virus-related cirrhosis: a randomized trialLaetitia Fartoux, Françoise Degos, Christian Trépo, et al.
Alimentary Pharmacology & Therapeutics|October 19, 2018
Long-term prognostic value of the FibroTest in patients with non-alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver diseaseMona Munteanu, Raluca Pais, Valentina Peta, et al.
Annals of the Rheumatic Diseases|November 15, 2015
Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC studyDavid Saadoun, Vincent Thibault, Si Nafa Si Ahmed, et al.
Journal of Hepatology|April 7, 2009
Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis BStefan Zeuzem, Edward Gane, Yun-Fan Liaw, et al.
Journal of Hepatology|December 3, 2013
Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest™) and transient elastography (FibroScan®)Thierry Poynard, Julien Vergniol, Yen Ngo, et al.
Journal of Clinical Medicine|August 23, 2020
Hepatitis C Clearance by Direct-Acting Antivirals Impacts Glucose and Lipid HomeostasisChristiana Graf, Tania Welzel, Dimitra Bogdanou, et al.
Journal of Hepatology|December 3, 2014
An extension of STARD statements for reporting diagnostic accuracy studies on liver fibrosis tests: the Liver-FibroSTARD standardsJérôme Boursier, Victor de Ledinghen, Thierry Poynard, et al.
Gastroenterology|October 19, 2005
A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patientsTing-Tsung Chang, Robert G Gish, Stephanos J Hadziyannis, et al.
Gastroenterology|March 10, 2017
Direct-Acting Antiviral Therapy Restores Immune Tolerance to Patients With Hepatitis C Virus-Induced Cryoglobulinemia VasculitisCloé Comarmond, Marlène Garrido, Stanislas Pol, et al.
Pageof 23

Showing results (181-190 of 222) with videos related to

Sort By:
Pageof 23
Plos One|July 4, 2008
An accurate definition of the status of inactive hepatitis B virus carrier by a combination of biomarkers (FibroTest-ActiTest) and viral loadYen Ngo, Yves Benhamou, Vincent Thibault, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|January 31, 2007
Effect of prolonged interferon therapy on the outcome of hepatitis C virus-related cirrhosis: a randomized trialLaetitia Fartoux, Françoise Degos, Christian Trépo, et al.
Alimentary Pharmacology & Therapeutics|October 19, 2018
Long-term prognostic value of the FibroTest in patients with non-alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver diseaseMona Munteanu, Raluca Pais, Valentina Peta, et al.
Annals of the Rheumatic Diseases|November 15, 2015
Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC studyDavid Saadoun, Vincent Thibault, Si Nafa Si Ahmed, et al.
Journal of Hepatology|April 7, 2009
Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis BStefan Zeuzem, Edward Gane, Yun-Fan Liaw, et al.
Journal of Hepatology|December 3, 2013
Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest™) and transient elastography (FibroScan®)Thierry Poynard, Julien Vergniol, Yen Ngo, et al.
Journal of Clinical Medicine|August 23, 2020
Hepatitis C Clearance by Direct-Acting Antivirals Impacts Glucose and Lipid HomeostasisChristiana Graf, Tania Welzel, Dimitra Bogdanou, et al.
Journal of Hepatology|December 3, 2014
An extension of STARD statements for reporting diagnostic accuracy studies on liver fibrosis tests: the Liver-FibroSTARD standardsJérôme Boursier, Victor de Ledinghen, Thierry Poynard, et al.
Gastroenterology|October 19, 2005
A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patientsTing-Tsung Chang, Robert G Gish, Stephanos J Hadziyannis, et al.
Gastroenterology|March 10, 2017
Direct-Acting Antiviral Therapy Restores Immune Tolerance to Patients With Hepatitis C Virus-Induced Cryoglobulinemia VasculitisCloé Comarmond, Marlène Garrido, Stanislas Pol, et al.
Pageof 23